8-K: Tivic Health Systems Announces $8.4 Million Securities Purchase Agreement

Tivic Health Systems enters into a securities purchase agreement for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants.

Summary

• Tivic Health Systems, Inc. has entered into a Securities Purchase Agreement with an investor for up to $8.4 million.
• The agreement involves the sale of up to 8,400 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase common stock.
• The offering will be conducted through six separate tranches, each closing subject to certain conditions.
• The initial tranche involves 700 shares for $700,000, with subsequent tranches increasing in size and occurring at 10-20 day intervals.
• At each tranche closing, the investor will also receive warrants to purchase common stock equal to 30% of the shares issuable upon conversion of the Series B Preferred issued at that closing.
• The warrants are immediately exercisable, expire five years from issuance, and have an initial exercise price equal to the average closing price of the company's common stock during the five trading days preceding each tranche closing.
• The investor has a right of first refusal on future variable rate transactions and the right to participate in subsequent financings for up to 20% of such financing.
• The company may be required to use 25% of proceeds from future financings to redeem Series B Preferred shares held by the investor.
• The investor is prohibited from converting shares or exercising warrants to the extent that it would result in ownership exceeding 19.99% of the company's outstanding common stock without stockholder approval.
• The company has agreed to file a proxy statement to obtain stockholder approval within 20 days of the execution date.
• The agreement contains termination provisions for the investor and will automatically terminate if any tranche closing has not occurred prior to December 31, 2025.
• The company also entered into a registration rights agreement, agreeing to file a registration statement covering the resale of the conversion shares and warrant shares within 15 days of the execution date.
• Craft Capital Management LLC acted as placement agent and will receive a cash fee equal to 8% of funds received from the investor.

Sentiment

Score: 6

Explanation: The announcement is neutral. It details a financing agreement, which is a common corporate action. The terms are fairly standard, with some potential benefits and drawbacks for the company.

Positives

• The agreement provides a significant capital infusion of up to $8.4 million.
• The structured tranche closings allow for phased funding and potential milestone-based releases.
• The investor's right of first refusal and participation in future financings could lead to continued support.
• The company has the option to pay dividends on the Series B Preferred in cash or by adding to the stated value of the shares (PIK Dividends).

Negatives

• The investor's right of first refusal could limit the company's options for future financing.
• The potential requirement to use 25% of future financing proceeds to redeem Series B Preferred shares could reduce available capital for operations.
• Stockholder approval is required for conversions/exercises exceeding 19.99% ownership, which could delay or limit the investor's ability to convert shares.
• The company is paying an 8% cash fee to the placement agent, which reduces the net proceeds from the offering.

Risks

• The consummation of the transactions is subject to various customary closing conditions.
• The investor has the ability to delay tranche closings if the average closing price of the company's common stock during the prior three trading days preceding a tranche closing date shall not be equal to or greater than the Floor Price.
• The agreement will automatically terminate if any tranche closing has not occurred prior to December 31, 2025.
• The company's stock price may be negatively impacted by the issuance of new shares upon conversion of the Series B Preferred and exercise of the warrants.

Future Outlook

The company intends to use the proceeds from the offering for general corporate purposes. The company is seeking stockholder approval to issue additional shares in accordance with applicable Nasdaq Rules.

Industry Context

This type of financing, involving preferred stock and warrants, is common for small-cap companies seeking capital. The right of first refusal and participation rights for the investor are typical terms to attract investment.

Comparison to Industry Standards

• Similar financings for companies of comparable size in the medical device industry often include warrants and convertible securities.
• The 8% placement agent fee is within the typical range for such transactions.
• The 10% dividend rate on the preferred stock is relatively high, suggesting the investor is seeking a higher return to compensate for the risk.
• The conversion price floor of $1.294 per share provides downside protection for the investor.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the Series B Preferred and exercise of the warrants.
• Employees may benefit from the increased capital, which could support operations and growth.
• Customers may benefit from improved products and services as a result of the financing.
• Suppliers may benefit from increased orders and business opportunities.
• Creditors may be impacted by the terms of the financing, including the potential redemption of Series B Preferred shares with proceeds from future financings.

Next Steps

• The company needs to file a registration statement covering the resale of the conversion shares and warrant shares.
• The company needs to file a proxy statement and obtain stockholder approval for the issuance of additional shares.
• The company needs to satisfy the closing conditions for each tranche and complete the sale of the securities.

Key Dates

Keywords

Series B Preferred Stock, Securities Purchase Agreement, Warrants, Financing, Convertible, Tivic Health Systems, Capital Raise, Registration Rights, Tranche Closing, Investor